shutterstock_1297486357_-billion-photos
Billion Photos / Shutterstock.com
1 October 2019Big PharmaSaman Javed

Brexit: The waiting game

As the UK’s proposed departure from the EU creeps closer, and a no-deal Brexit—leaving without an agreement as to what the future relationship between the remaining 27 members and the UK will be—looks a very real possibility, there is a growing concern across the country’s life sciences industry about how much this will impact what they do, and how much is still uncertain.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
1 July 2026   Otsuka v Sun Pharma could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in the country.
Big Pharma
18 June 2026   Despite a slowdown in US patent litigation, life sciences remains one of the most active sectors—but companies are using a wider than ever IP toolkit, says a new study.
Big Pharma
15 April 2026   The Danish pharma giant is turning to artificial intelligence as it faces patent expiry, falling shares and intensifying competition from Eli Lilly.